Pyrrole compounds that modulate HSP90 activity

1. A method of treating a proliferative disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof,

wherein:

each R 1 and R 2 is independently —NR 10 R 11 , —OR 7 , or —SR 7 ;

R 3 is hydrogen, —X 50 R 50 , alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteraralkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteraralkyl represented by R 3 is optionally and independently substituted;

each R 4 and R 5 is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteraralkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteraralkyl represented by R 4 or R 5 is optionally and independently substituted;

each R 7 is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteraralkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteraralkyl represented by R 7 is optionally and independently substituted;

each R 10 and R 11 is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteraralkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteraralkyl represented by R 10 or R 11 is optionally and independently substituted; or

R 10 and R 11 , taken together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl or an optionally substituted heteroaryl;

R 50 is an optionally substituted aryl or an optionally substituted heteroaryl;

X 50 is a divalent group selected from a C 1 -C 4 alkylene, NR 7 , C(O), C(S), C(NR 7 ), and S(O) p ;

Y is O or S;

each Z is independently alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, halo, cyano, nitro, guanadino, or alkoxy, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl represented by Z are optionally and independently substituted;

each optional substituent for an alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl, and heteroaralkyl is independently an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteraralkyl, heteroalkyl, alkoxy, halo, cyano, nitro, or guanadino;

each p is independently 0, 1 or 2; and

n is 0, 1, 2, or 3.

2. The method of claim 1 , wherein the proliferative disorder is a cancer.

3. The method of claim 2 , wherein the cancer is a c-Kit associated cancer.

4. The method of claim 2 , wherein the cancer is a BCR-ABL associated cancer.

5. The method of claim 2 , wherein the cancer is a FLT3 associated cancer.

6. The method of claim 2 , wherein the cancer is an EGFR associated cancer.

7. The method of claim 1 , wherein the subject is human.

8. The method of claim 2 , wherein the cancer is a non-Hodgkin's lymphoma.

9. The method of claim 8 , wherein the non-Hodgkin's lymphoma is a B-cell non-Hodgkin's lymphoma.

10. The method of claim 9 , wherein the B-cell non-Hodgkin's lymphoma is selected from the group consisting of Burkitt's lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, nodal marginal zone B-cell lymphoma, plasma cell neoplasms, small lymphocytic lymphoma/chronic lymphocytic leukemia, mantle cell lymphoma, and lymphoplamacytic lymphoma/Waldenstrom macroglobulinemia.

11. The method of claim 8 , wherein the non-Hodgkin's lymphoma is a T-cell non-Hodgkin's lymphoma.

12. The method of claim 11 , wherein the T-cell non-Hodgkin's lymphoma is selected from the group consisting of anaplastic large-cell lymphoma, precursor-T-cell lymphoblastic leukemia/lymphoma, unspecified peripheral T-cell lymphoma, and angioimmunoblastic T-cell lymphoma.

13. The method of claim 1 , wherein the proliferative disorder is an inflammatory disorder.

14. The method of claim 13 , wherein the inflammatory disorder is selected from the group consisting of a transplant rejection, a chronic inflammatory disorder of the joints, an inflammatory bowel disease, an inflammatory lung disorder, an inflammatory disorder of the eye, a chronic inflammatory disorder of the gums, an inflammatory disease of the kidney, an inflammatory disorder of the skin, an inflammatory disease of the central nervous system, an inflammatory disease of the heart, and a systemic inflammation.